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Stroke in Patients With Acute Coronary Syndromes
Incidence and Outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable
Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial
Kenneth W. Mahaffey, MD; Robert A. Harrington, MD; Maarten L. Simoons, MD;
Christopher B. Granger, MD; Carmelo Graffagnino, MD; Mark J. Alberts, MD;
Daniel T. Laskowitz, MD; Julie M. Miller, MD; Michael A. Sloan, MD; Lisa G. Berdan, PA-C, MHS;
Cynthia M. MacAulay, MS; A. Michael Lincoff, MD; Jaap Deckers, MD; Eric J. Topol, MD;
Robert M. Califf, MD; for the PURSUIT Investigators
Background—The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few
trials in this patient population have been large enough to provide stable estimates of stroke rates.
Methods and Results—We studied the 10 948 patients with acute coronary syndromes without persistent ST-segment
elevation who were randomly assigned to placebo or the platelet glycoprotein IIb/IIIa receptor inhibitor eptifibatide
in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
(PURSUIT) trial to determine stroke rates, stroke types, clinical outcomes in patients with stroke, and independent
baseline clinical predictors for nonhemorrhagic stroke. Stroke occurred in 79 (0.7%) patients, with 66 (0.6%)
nonhemorrhagic, 6 intracranial hemorrhages, 3 cerebral infarctions with hemorrhagic conversion, and 4 of
uncertain cause. There were no differences in stroke rates between patients who received placebo and those
assigned high-dose eptifibatide (odds ratios and 95% confidence intervals 0.82 [0.59, 1.14] and 0.70 [0.49, 0.99],
respectively). Of the 79 patients with stroke, 17 (22%) died within 30 days, and another 26 (32%) were disabled
by hospital discharge or 30 days, whichever came first. Higher heart rate was the most important baseline clinical
predictor of nonhemorrhagic stroke, followed by older age, prior anterior myocardial infarction, prior stroke or
transient ischemic attack, and diabetes mellitus. These factors were used to develop a simple scoring nomogram
that can predict the risk of nonhemorrhagic stroke.
Conclusions—Stroke was an uncommon event in patients with acute coronary syndromes in the PURSUIT trial. These
strokes are, however, associated with substantial morbidity and mortality rates. The majority of strokes were of
nonhemorrhagic causes. Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant
effect on nonhemorrhagic stroke was observed. We developed a useful nomogram for assigning baseline nonhemor-
rhagic stroke risk in this patient population. (Circulation. 1999;99:2371-2377.)
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The incidence of stroke in patients with acute myocardialinfarction treated with and those without thrombolytic
therapy has been well established.1–13 The incidence of stroke
in patients with acute coronary syndromes without persistent
ST-segment elevation is less clearly defined, as few trials in
this patient population have been large enough to provide a
stable estimate of stroke rates given the relative infrequency
of this adverse event. In the 2 largest trials of this population
to date, stroke occurred in 0.8% of patients with acute
coronary syndromes not treated with thrombolysis.14,15 The
majority of these strokes were nonhemorrhagic. Risk factors
for stroke in this patient population have not been previously
analyzed.
The recently completed Platelet Glycoprotein IIb/IIIa in
Unstable Angina: Receptor Suppression Using Integrilin Ther-
apy (PURSUIT) trial is the largest trial to date of patients with
acute coronary syndromes without persistent ST-segment eleva-
tion.16 We prospectively collected information about patients
with suspected stroke to determine the incidence of stroke,
stroke types, outcomes in patients with stroke, and the indepen-
dent baseline clinical and demographic risk factors for nonhem-
orrhagic stroke in this patient population.
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Methods
Study Population
The PURSUIT trial enrolled 10 948 patients in 726 hospitals in 27
countries. Enrollment criteria have been published16: In brief, pa-
tients with symptoms of ischemic chest pain at rest lasting 10
minutes or longer within the previous 24 hours that was accompanied
by either transient ST-segment elevation .0.5 mm, transient or
persistent ST-segment depression .0.5 mm, or T-wave inversion
.1 mm within 12 hours of the chest pain; or had a creatine kinase
myocardial enzymes fraction above the upper limit of normal for that
hospital. Exclusion criteria included persistent ST-segment elevation
.1 mm; evidence of bleeding; systolic blood pressure .200 mm Hg
or diastolic blood pressure .110 mm Hg; major surgery within 6
weeks; a nonhemorrhagic stroke within 30 days or any history of
hemorrhagic stroke; renal failure; or treatment with thrombolytic
therapy within 24 hours.
Patients were randomly assigned in double-blind fashion to an
intravenous bolus and infusion of placebo, 180 mm/kg bolus plus
infusion of 1.3 mg/kg per minute of eptifibatide, or 180 mg/kg bolus
plus infusion of 2.0 mg/kg per minute of eptifibatide. Per prespeci-
fied plan, after 3218 patients were randomized, an independent Data
and Safety Monitoring Committee reviewed the safety data. The
committee recommended dropping the lower dose because the high
dose had an acceptable safety profile.
A study drug was to be infused until hospital discharge or up to 72
hours, whichever came first (or up to 96 hours in patients undergoing
percutaneous intervention at 72 hours). All patients were to receive
daily aspirin, and heparin was recommended but not required.
Intravenous heparin was to be given as a 5000 U bolus and 1000 U/h
infusion with adjustment to maintain activated partial thromboplastin
time in the 50 to 70 seconds range. Lower doses were recommended
for patients who weighed ,70 kg. Other concomitant medications,
diagnostic cardiac procedures, or percutaneous or surgical interven-
tions were at the discretion of the treating physician.
Stroke Classification
Stroke was defined as an acute new neurological deficit resulting in
death or lasting for .24 hours. A Stroke Adjudication Committee
(see Appendix) was established to independently adjudicate and
categorize all suspected strokes. Patients with suspected strokes were
identified from the Case Report Form.
The evaluation of patients with stroke was prospectively planned.
The protocol specified that all patients with a new neurological
deficit undergo complete evaluation including brain imaging. Clin-
ical notes, discharge summaries, neurological or neurosurgical con-
sultation notes, autopsy reports, and results of computed tomo-
graphic or magnetic resonance imaging (MRI) studies were collected
on all patients with suspected stroke. The committee reviewed all
available medical records and determined by consensus if a stroke
did or did not occur and if so, categorized the type of stroke. The
Stroke Adjudication Committee members were blinded to treatment
assignment.
Stroke Categories
Strokes were divided into 4 main categories: primary hemorrhagic,
nonhemorrhagic, hemorrhagic conversion of infarct, and uncertain.
Primary hemorrhagic was diagnosed if a focal collection of intracra-
nial blood was seen on brain imaging or at autopsy and was not
believed to represent hemorrhagic conversion. Nonhemorrhagic
stroke was categorized if there was a low-density lesion on computed
tomography, high-intensity lesion on MRI, or clinical evidence of a
stroke and no focal collection of intracranial hemorrhage on brain
imaging studies or at autopsy. Hemorrhagic conversion was diag-
nosed if blood was present within an area of cerebral infarction, but
the event was not thought to represent a primary hemorrhagic stroke.
The uncertain classification was used if there was clinical evidence
of a stroke and no brain imaging or autopsy data were available to
determine the type of stroke.
Patient Functional Assessment
Functional status was determined for all patients with stroke at
hospital discharge or 30 days, whichever came first. Patients were
classified by site investigators as not disabled if they had no deficit
(no sequelae) or minor deficits (functional status unchanged) and as
disabled if they had moderate deficits (significant limitations of
activity) or severe deficits (unable to live independently or return to
work). The correlation of this classification of disability and direct
patient interviews in stroke survivors has been shown to be
excellent.9
Statistical Analysis
Continuous variables are shown as medians with 25th and 75th
percentiles. Discrete variables are shown as frequencies and percent-
ages. Stroke data for all 10 948 patients are included. Analyses that
include comparisons between treatment groups only include the 9461
patients assigned placebo or high-dose eptifibatide because the
low-dose eptifibatide group was not contemporaneous with the other
2 groups as the result of discontinuation of the low-dose arm after the
interim analysis by the Data Safety and Monitoring Board (see
Methods). Logistic regression modeling was used to determine the
univariable predictors of nonhemorrhagic stroke and the multivari-
able baseline risk factors for nonhemorrhagic stroke. Predictors were
tested with the use of the Wald or likelihood x2 test. Results are
presented as odds ratios and 95% confidence intervals.
A scoring nomogram was created from the coefficients from the
baseline multivariable regression modeling. Each independent pre-
dictor was assigned a score according to its predictive value. The
sum of the scores indicates the probability of a nonhemorrhagic
stroke, based on baseline predictors for individual patients.17
Results
A total of 79 (0.7%) strokes occurred within 30 days in the
10 948 patients enrolled in the PURSUIT trial. Table 1 shows
the type of strokes by treatment assignment. Nonhemorrhagic
stroke was the most common stroke type. Specifically,
nonhemorrhagic stroke was observed in 28 (0.6%) high-dose
eptifibatide patients and in 33 (0.7%) placebo patients. The
median (25th, 75th) time to onset of nonhemorrhagic stroke
symptoms was 6.5 (3, 12) days (Figure 1). The clinical
outcomes for patients with stroke are shown in Table 2.
Overall, 54% of patients with stroke died or were disabled at
the time of hospital discharge or 30-day follow-up, whichever
came first.
Table 3 shows the baseline clinical characteristics for
patients with and those without stroke and for patients with
nonhemorrhagic stroke. Patients with stroke were older and
more often female, had lower body weight and higher heart
rate, and more frequently had prior myocardial infarction,
diabetes mellitus, history of hypertension, hypercholesterol-
emia, coronary artery bypass surgery, and history of stroke or
TABLE 1. Incidence of Stroke by 30-Day Follow-Up
Placebo
(n54739)
Eptifibatide*
(n56209)
Total
(n510 948)
Primary hemorrhagic 2 (,0.1%) 4 (,0.1%) 6 (,0.1%)
Nonhemorrhagic 33 (0.7%) 33 (0.5%) 66 (0.6%)
Cerebral infarction with
hemorrhagic conversion
1 (,0.1%) 2 (,0.1%) 3 (,0.1%)
Uncertain 3 (,0.1%) 1 (,0.1%) 4 (,0.1%)
Total 39 (0.8%) 40 (0.6%) 79 (0.7%)
Values are n (%).
*Includes both low-dose and high-dose patients.
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transient ischemic attack. Patients with stroke more com-
monly experienced adverse in-hospital events including hy-
potension, atrial fibrillation, congestive heart failure, cardio-
genic shock, and coronary artery bypass surgery (Table 4).
Table 5 shows the univariable baseline factors associated
with nonhemorrhagic stroke. Five independent baseline clin-
ical and demographic predictors of stroke occurring by
30-day follow-up were identified (Table 6). Higher heart rate
was the most important independent baseline clinical predic-
tor; older age, previous anterior myocardial infarction, prior
stroke or transient ischemic attack, and history of diabetes
mellitus were the other statistically significant predictors.
Other possible but not statistically significant predictors were
prior percutaneous intervention (P50.09), history of aspirin
use (P50.06), and history of hypercholesterolemia (P50.09).
The predicted probability in individual patients for nonhem-
orrhagic stroke within 30-day follow-up can be calculated by
using the nomogram in Figure 2.
Discussion
In the PURSUIT trial of almost 11 000 patients, the overall
stroke rate through 30-day follow-up was 0.7%. The majority
of these strokes were not hemorrhagic. We identified 5 easily
determined independent baseline clinical and demographic
risk factors for nonhemorrhagic stroke in the PURSUIT
population (higher heart rate, older age, prior anterior myo-
cardial infarction, prior stroke or transient ischemic attack,
and diabetes mellitus).
In patients with ST-segment elevation, acute myocardial
infarction, the incidence of stroke in the era before the routine
use of thrombolytic therapy was 1.7% to 3.2%.1–5 In the
thrombolytic era, the incidence of stroke has decreased, but
Figure 1. Cumulative frequency distribution of days from enrollment to nonhemorrhagic stroke in PURSUIT trial.
TABLE 2. Clinical Outcomes in Stroke Patients by Stroke Type
Outcome
Primary
Hemorrhagic
(n56)
Nonhemorrhagic
(n566)
Infarct With
Hemorrhagic
Conversion
(n53)
Uncertain
(n54)
Total
(n579)
Death 4 (67%) 11 (17%) 1 (33%) 1 (25%) 17 (22%)
Severe deficit 0 (0%) 10 (15%) 1 (33%) 0 (0%) 11 (14%)
Moderate deficit 1 (17%) 14 (21%) 0 (0%) 0 (0%) 15 (19%)
Mild deficit 0 (0%) 14 (21%) 0 (0%) 1 (25%) 15 (19%)
No deficit 0 (0%) 6 (9%) 0 (0%) 1 (25%) 7 (9%)
Unknown 1 (17%) 11 (17%) 1 (33%) 1 (25%) 14 (18%)
Death or disabled 5 (83%) 35 (53%) 2 (67%) 1 (25%) 43 (54%)
Values are n (%).
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there is a higher proportion of intracranial hemorrhage
(0.07% to 1.5%) and a lower rate of nonhemorrhagic stroke
(0.1% to 1.3%).6–12 The rates observed for nonhemorrhagic
stroke in the current study were similar to those for patients
with acute myocardial infarction treated with thrombolysis
and, as would be expected, the incidence of intracranial
hemorrhage was lower. The observed rate of intracranial
hemorrhage was 0.05% (6/10948) without evidence of an
increase in the eptifibatide groups compared with placebo (4
patients vs 2 patients). These data support the safety of
eptifibatide regarding intracranial hemorrhage.
The Global Use of Strategies to Open Occluded Arteries in
acute coronary syndromes (GUSTO IIb) trial14 was the
largest trial of patients with acute coronary syndromes prior
to PURSUIT. In GUSTO IIb, 8011 patients with acute
coronary syndromes without persistent ST-segment elevation
were randomly assigned to intravenous heparin or the novel
antithrombin, hirudin. All patients were to be treated with
aspirin. The overall incidence of stroke was 0.8%. Nonhem-
orrhagic stroke occurred in 0.5% of patients and 0.09% of
patients had a primary hemorrhagic stroke.14 No difference in
stroke rates was observed by treatment assignment. These
data are similar to the stroke rates in PURSUIT, in which
patients were to be treated with heparin and aspirin and
randomly assigned to the glycoprotein IIb/IIIa receptor inhib-
itor eptifibatide or to placebo. The patients in PURSUIT were
more often female (35% vs 33%), younger (64 vs 66 years),
heavier (78 vs 76 kg), and had lower enrollment systolic
blood pressure (130 vs 139 mm Hg), lower heart rate (72 vs
74 bpm) and were more likely to have a history of diabetes
(23% vs 19%), hypertension (55% vs 48), or previous
coronary intervention (13% vs 12%) compared with the
GUSTO IIb population. However, the impact of these factors
on stroke rates in the 2 trials is unknown.
No previous studies have determined the risk factors for
stroke in the unstable angina population to use for compari-
son with our results. In the GUSTO I trial of .41 000 patients
treated with thrombolysis for acute myocardial infarction, the
baseline independent risk factors for nonhemorrhagic stroke
were similar to those identified for the PURSUIT popula-
tion.13 In GUSTO I, as in PURSUIT, older age, higher heart
rate, history of stroke or transient ischemic attack, and
diabetes mellitus were independent baseline predictors of
stroke.18 Prior anterior myocardial infarction was not a risk
factor in the GUSTO I stroke prediction model, but prior
angina was an independent predictor. A history of hyperten-
sion was also an independent predictor in the GUSTO I
population, but it was not in the PURSUIT nonhemorrhagic
stroke model, although it did achieve borderline statistical
significance in univariable analysis. The reason higher heart
rate is an independent predictor for nonhemorrhagic stroke is
not clear from these data, but heart rate may correlate with
larger infarctions that predispose patients to a higher likeli-
hood of atrial arrhythmia and left ventricular thrombi.
The clinical outcomes of stroke patients with unstable
angina/non–Q-wave myocardial infarction have not been
previously reported. In PURSUIT, stroke was associated with
substantial morbidity and mortality rates. In GUSTO I, the
percentage of nonhemorrhagic stroke patients who died or
TABLE 3. Baseline Characteristics of Stroke Patients
Nonhemorrhagic
Stroke (n566)
All Stroke
(n579)
No Stroke
(n510 869)
Overall
(n510 948)
Age 69 (61, 75) 70 (61, 75) 64 (55, 71) 64 (55, 71)
Female sex 30 (45%) 35 (44%) 3822 (35%) 3857 (35%)
Systolic blood pressure 130 (115, 149) 130 (115, 146) 130 (116, 145) 130 (116, 145)
Diastolic blood pressure 72 (65, 81) 72 (65, 80) 75 (67, 83) 75 (67, 83)
Heart rate 75 (65, 88) 76 (65, 90) 72 (62, 80) 72 (62, 80)
Prior anterior MI 12 (18%) 14 (18%) 958 (9%) 972 (9%)
Prior MI 27 (41%) 30 (38%) 3519 (32%) 3549 (33%)
Height, cm 169 (160, 175) 169 (161, 175) 170 (163, 176) 170 (163, 176)
Time to treatment, min 35 (20, 90) 32 (16, 83) 30 (15, 57) 30 (15, 57)
History of smoking 21 (32%) 24 (30%) 3556 (33%) 3580 (33%)
Current smoker 19 (29%) 22 (28%) 3077 (28%) 3099 (28%)
Diabetes mellitus 25 (38%) 28 (35%) 2453 (23%) 2481 (23%)
Weight, kg 72 (65, 90) 73 (65, 89) 78 (69, 88) 78 (69, 88)
Previous CABG 12 (18%) 13 (16%) 1282 (12%) 1295 (12%)
Previous PTCA 4 (6%) 4 (5%) 1425 (13%) 1429 (13%)
Previous angina 53 (80%) 64 (81%) 8801 (81%) 8865 (81%)
History of hypertension 44 (67%) 50 (63%) 5980 (55%) 6030 (55%)
History of hypercholesterolemia 33 (50%) 37 (47%) 4490 (42%) 4527 (42%)
Family history of CAD 27 (41%) 30 (39%) 3808 (35%) 3838 (35%)
Prior stroke/TIA 10 (15%) 12 (15%) 647 (6%) 659 (6%)
MI indicates myocardial infarction; CAD, coronary artery disease; TIA, transient ischemic attack.
Values are n (%) or median (25th, 75th) where appropriate.
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were disabled was comparable with that in the PURSUIT
population (57% vs 54%).9
The incidence of nonhemorrhagic stroke in patients as-
signed high-dose eptifibatide compared with placebo was
similar (0.6% vs 0.7%, respectively; P50.53). Treatment
assignment was not a statistically significant predictor of
nonhemorrhagic stroke in the univariable or multivariable
analyses. The overall number of strokes was small; therefore
definitive conclusions cannot be made about the potential
risks or benefits of glycoprotein IIb/IIIa receptor blockade on
the incidence of nonhemorrhagic stroke from these data. A
lower incidence of nonhemorrhagic stroke in the eptifibatide
group would have been consistent with the known benefits of
antiplatelet therapy in decreasing the incidence of stroke in
patients with acute myocardial infarction or prior stroke as
well as in other high-risk patient groups including unstable
angina.19 Ongoing studies of prolonged oral glycoprotein
TABLE 4. In-Hospital Cardiac Events, Medications, and Procedures
Nonhemorrhagic
Stroke (n566)
All Stroke
(n579)
No Stroke
(n510 869)
Overall
(n510 948)
Ejection fraction, % 50.5 (40, 60) 50 (40, 60) 55 (45, 65) 55 (45, 65)
Hypotension requiring treatment 14 (21%) 16 (20%) 714 (7%) 730 (7%)
Atrial fibrillation/flutter* 18 (27%) 20 (26%) 713 (7%) 733 (7%)
Aspirin during infusion 57 (86%) 69 (87%) 10 092 (93%) 10 161 (93%)
Heparin during infusion 62 (94%) 72 (91%) 9730 (90%) 9802 (90%)
Cardiac catheterization
Total 51 (77%) 58 (73%) 6842 (63%) 6900 (63%)
Before stroke onset† 48 (73%) 55 (70%)
PCI
Total 8 (12%) 11 (14%) 2803 (26%) 2814 (26%)
Before stroke onset† 7 (11%) 10 (13%)
CABG
Total 33 (50%) 35 (44%) 1676 (15%) 1711 (16%)
Before stroke onset† 33 (50%) 35 (44%)
IABP
Total 11 (17%) 11 (14%) 282 (3%) 293 (3%)
Before stroke onset† 11 (17%) 11 (14%)
Congestive heart failure
Total 7 (11%) 8 (10%) 592 (5%) 600 (5%)
Before stroke onset† 4 (6%) 5 (6%)
Cardiogenic shock
Total 7 (11%) 8 (10%) 266 (2%) 274 (3%)
Before stroke onset† 5 (8%) 6 (8%)
PCI indicates percutaneous coronary intervention; IABP, intra-aortic balloon pump.
Values are n (%).
*After enrollment.
†Occurring on same day as or before stroke onset.
TABLE 5. Univariable Baseline Predictors of
Nonhemorrhagic Stroke
Likelihood
Ratio x2 P Odds Ratio
Age (per 10 years) 11.3 ,0.001 1.48
Higher heart rate (per 10 bpm) 10.7 0.001 1.29
Diabetes mellitus 7.8 0.005 2.10
Prior stroke or TIA 7.1 0.008 2.81
Prior aspirin use 5.8 0.016 1.95
Prior CHF 5.6 0.018 2.16
Prior anterior MI 5.6 0.018 2.30
History of hypertension 3.7 0.055 1.64
Female sex 2.9 0.087 1.53
TIA indicates transient ischemic attack; CHF, congestive heart failure; and
MI, myocardial infarction.
TABLE 6. Independent Baseline Clinical and Demographic
Predictors of Nonhemorrhagic Stroke
Wald x2 P
Odds Ratio
(95% CI)
Higher heart rate (per 10 bpm) 8.5 0.004 1.25 (1.08–1.45)
Older age (per 10 years) 6.6 0.01 1.38 (1.08–1.77)
Prior anterior MI 6.6 0.01 2.30 (1.22–4.34)
Prior stroke or TIA 5.4 0.02 2.27 (1.14–4.54)
Diabetes mellitus 4.4 0.03 1.73 (1.03–2.89)
MI indicates myocardial infarction; TIA, transient ischemic attack.
Model x2531.512; 10 812 patients were included in model, with 64
nonhemorrhagic strokes (2 of the 66 nonhemorrhagic stroke patients excluded
because of missing key variables). C-index50.685.
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IIb/IIIa receptor antagonists in patients with acute coronary
syndromes and cerebrovascular disease will provide more
definitive data about treatment benefits with such agents in
these patient populations.
Study Limitations
Our study has several limitations. The baseline predictors of
stroke may not account for all the risk for stroke in this patient
population. Fifty percent of nonhemorrhagic strokes occurred
.6.5 days after enrollment, and we were not able to account
for in-hospital procedures or events that may be associated
with stroke, primarily because of the relatively small sample
size and limited regression modeling that could be performed.
There was no systematic assessment of the cardiac rhythm at
the time of study enrollment; therefore atrial fibrillation was
not included in the prediction model. However, only 159
(1.5%) patients had atrial fibrillation reported on the Case
Report Form before or within 4 hours of study enrollment,
and only 2 of these patients had nonhemorrhagic stroke.
The mechanism of the strokes, particularly the nonhemor-
rhagic strokes, was not assessed. However, systematic review
of all suspected strokes by the Stroke Adjudication Commit-
tee, which included analysis of computed axial tomographic
data, MRI data, or autopsy results in 80% of patients, allowed
determination of stroke types in a majority of cases, and the
number of “unknowns” was small.
The logistic regression model and associated scoring no-
mogram were developed with the use of only 64 nonhemor-
rhagic strokes and therefore require validation in a larger
patient population. However, the similarity to the prediction
model from the GUSTO-I trial is supportive. Finally, these
results are only applicable to patients with acute coronary
syndromes without persistent ST-segment elevation treated
with heparin and aspirin and should not be generalized to all
patients with acute coronary syndromes.
Conclusions
Stroke was an uncommon event in patients with acute
coronary syndromes without persistent ST-segment elevation
treated with antiplatelet and antithrombin therapy in the
PURSUIT trial. The majority of strokes were of nonhemor-
rhagic causes. Despite the low incidence of stroke, its
prevalence is substantial because more than 1 million patients
present each year with non–ST-segment elevation acute
coronary syndromes to hospitals in the United States, with
similar numbers in Western Europe. Therefore .7000 pa-
tients with acute coronary syndromes in the United States
alone have a stroke, and these strokes are associated with
significant morbidity and mortality rates. The use of eptifi-
batide, a glycoprotein IIb/IIIa receptor antagonist, was not
associated with an increased incidence of intracranial hemor-
rhage, and we observed no significant effect on the occur-
rence of nonhemorrhagic stroke. Higher heart rate, older age,
prior stroke or transient ischemic attack, prior anterior myo-
cardial infarction, and diabetes mellitus were independent
baseline predictors of nonhemorrhagic stroke. Physicians can
use these factors to determine the probability of nonhemor-
rhagic stroke with a simple scoring nomogram (Figure 2).
The impact of stroke risk assessment on patient management
requires further study.
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